Intra-Dialytic Hemoglobin Changes and Cardiovascular Events: A Cohort Study on Dialysis Outcomes and Practice Patterns in Japan

Overview

Journal Am J Nephrol

Publisher Karger

Specialty Nephrology

Date 2019 Sep 6

PMID 31487713

Citations 1

Authors

Takashi Hara

Miho Kimachi

Tatsuyoshi Ikenoue

Tadao Akizawa

Shunichi Fukuhara

Yosuke Yamamoto

Affiliations

Soon will be listed here.

Abstract

Background: Ultrafiltration during hemodialysis (HD) causes hemoconcentration. Little is known about the relationships between intra-dialytic changes in hemoglobin concentration and cardiovascular events. Thus, this study aimed to elucidate the relationships between intra-dialytic changes in hemoglobin concentration and cardiovascular events among HD patients.

Methods: This prospective cohort study was based on the Japanese Dialysis Outcomes and Practice Pattern Study phases 4 and 5. The predictor was the ratio of post-dialysis hemoglobin concentration to pre-dialysis hemoglobin concentration (post-Hb/pre-Hb) at baseline. The primary outcome was major adverse cardiovascular events (MACEs). Hazard ratios (HRs) were estimated using a Cox model for the association between post-Hb/pre-Hb and MACEs, adjusting for potential confounders.

Results: A total of 865 patients were enrolled. During a median follow-up of 2.6 years, 145 (16.8%) patients developed MACEs. Patients were divided into 4 categories according to baseline post-Hb/pre-Hb (<1.0, ≥1.0 to <1.1, ≥1.1 to <1.2, and ≥1.2). The multivariable-adjusted HRs for MACEs were 1.69 (95% CI 1.36-2.10), 1.29 (95% CI 1.10-1.51), and 1.31 (95% CI 1.02-1.68) in patients with post-Hb/pre-Hb ratios of <1.0, ≥1.0 to <1.1, and ≥1.2, respectively, compared with the reference post-Hb/pre-Hb ratio of ≥1.1 to <1.2. Cubic spline analyses revealed a U-shaped association between post-Hb/pre-Hb and MACEs.

Conclusion: High and low intra-dialytic changes in hemoglobin concentration are associated with a high risk of MACEs in patients undergoing HD.

Citing Articles

Analysis of prefrontal cerebral blood volume and flow changes in ESKD patients undergoing hemodialysis using functional near-infrared spectroscopy.

Heo C, Yi J, Park K, Lee D, Lee Y, Park B Ren Fail. 2024; 46(2):2387426.

PMID: 39135525 PMC: 11328595. DOI: 10.1080/0886022X.2024.2387426.

References

Jaeger J, Mehta R . Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol. 1999; 10(2):392-403. DOI: 10.1681/ASN.V102392. View

Obi Y, Rhee C, Mathew A, Shah G, Streja E, Brunelli S . Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. J Am Soc Nephrol. 2016; 27(12):3758-3768. PMC: 5118484. DOI: 10.1681/ASN.2015101142. View

Thomson G, Waterhouse K, MCDONALD Jr H, Friedman E . Hemodialysis for chronic renal failure. Clinical observations. Arch Intern Med. 1967; 120(2):153-67. View

Assimon M, Wenger J, Wang L, Flythe J . Ultrafiltration Rate and Mortality in Maintenance Hemodialysis Patients. Am J Kidney Dis. 2016; 68(6):911-922. PMC: 5123913. DOI: 10.1053/j.ajkd.2016.06.020. View

Sinha A, Agarwal R . Can chronic volume overload be recognized and prevented in hemodialysis patients? The pitfalls of the clinical examination in assessing volume status. Semin Dial. 2009; 22(5):480-2. DOI: 10.1111/j.1525-139X.2009.00641.x. View

Pisoni R, Gillespie B, Dickinson D, Chen K, Kutner M, Wolfe R . The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004; 44(5 Suppl 2):7-15. DOI: 10.1053/j.ajkd.2004.08.005. View

Levick J, Michel C . Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res. 2010; 87(2):198-210. DOI: 10.1093/cvr/cvq062. View

Saran R, Bragg-Gresham J, Levin N, Twardowski Z, Wizemann V, Saito A . Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006; 69(7):1222-8. DOI: 10.1038/sj.ki.5000186. View

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

10.

Saran R, Bragg-Gresham J, Rayner H, Goodkin D, Keen M, van Dijk P . Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 2003; 64(1):254-62. DOI: 10.1046/j.1523-1755.2003.00064.x. View

11.

Steuer R, Leypoldt J, Cheung A, Harris D, Conis J . Hematocrit as an indicator of blood volume and a predictor of intradialytic morbid events. ASAIO J. 1994; 40(3):M691-6. DOI: 10.1097/00002480-199407000-00087. View

12.

Matsubara Y, Kimachi M, Fukuma S, Onishi Y, Fukuhara S . Development of a new risk model for predicting cardiovascular events among hemodialysis patients: Population-based hemodialysis patients from the Japan Dialysis Outcome and Practice Patterns Study (J-DOPPS). PLoS One. 2017; 12(3):e0173468. PMC: 5342257. DOI: 10.1371/journal.pone.0173468. View

13.

Lee M, Doh F, Kim C, Koo H, Oh H, Park J . Interdialytic weight gain and cardiovascular outcome in incident hemodialysis patients. Am J Nephrol. 2014; 39(5):427-35. DOI: 10.1159/000362743. View

14.

Buuren S, Boshuizen H, Knook D . Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999; 18(6):681-94. DOI: 10.1002/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r. View

15.

van der Sande F, Kooman J, Leunissen K . Intradialytic hypotension--new concepts on an old problem. Nephrol Dial Transplant. 2000; 15(11):1746-8. DOI: 10.1093/ndt/15.11.1746. View

16.

Movilli E, Pertica N, Camerini C, Cancarini G, Brunori G, Scolari F . Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis. 2002; 39(4):850-3. DOI: 10.1053/ajkd.2002.32007. View

17.

Nishiwaki H, Hasegawa T, Koiwa F, Hamano T, Masakane I . The association of the difference in hemoglobin levels before and after hemodialysis with the risk of 1-year mortality in patients undergoing hemodialysis. Results from a nationwide cohort study of the Japanese Renal Data Registry. PLoS One. 2019; 14(1):e0210533. PMC: 6328160. DOI: 10.1371/journal.pone.0210533. View

18.

Steuer R, Leypoldt J, Cheung A, Senekjian H, Conis J . Reducing symptoms during hemodialysis by continuously monitoring the hematocrit. Am J Kidney Dis. 1996; 27(4):525-32. DOI: 10.1016/s0272-6386(96)90163-8. View

19.

Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C . The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant. 2009; 24(5):1574-9. PMC: 2668965. DOI: 10.1093/ndt/gfn707. View

20.

Wang C, Kane R, Levenson M, Kelman J, Wernecke M, Lee J . Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare. JAMA Intern Med. 2016; 176(12):1818-1825. DOI: 10.1001/jamainternmed.2016.6520. View